Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TDI 01

Next Previous
Drug Profile

TDI 01

Alternative Names: GV-101; OV-888; TDI-01

Latest Information Update: 14 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Tide Pharmaceutical
  • Developer Beijing Tide Pharmaceutical; Graviton; Ovid Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Neuroprotectants; Obesity therapies; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic pulmonary fibrosis
  • Phase II Hepatic fibrosis; Non-alcoholic steatohepatitis; Obesity
  • Phase I/II Graft-versus-host disease
  • Phase I Central nervous system cavernous haemangioma
  • Preclinical CNS disorders; Friedreich's ataxia
  • Discontinued Cancer; Viral infections

Most Recent Events

  • 11 Aug 2026 Preclinical trials in Friedreich's ataxia in USA (PO) prior to August 2026
  • 11 Aug 2026 Pharmacodynamics data from a preclinical studies in Friedreich's-ataxia released by Graviton BioScience
  • 11 Aug 2026 Graviton BioScience Corporation plans a phase II trial for Friedreich's-ataxia in USA in first quarter of 2027

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top